CN1298738C - 修饰的麻疹病毒v蛋白 - Google Patents

修饰的麻疹病毒v蛋白 Download PDF

Info

Publication number
CN1298738C
CN1298738C CNB018116426A CN01811642A CN1298738C CN 1298738 C CN1298738 C CN 1298738C CN B018116426 A CNB018116426 A CN B018116426A CN 01811642 A CN01811642 A CN 01811642A CN 1298738 C CN1298738 C CN 1298738C
Authority
CN
China
Prior art keywords
virus
protein
amino acid
mutation
hav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018116426A
Other languages
English (en)
Chinese (zh)
Other versions
CN1437613A (zh
Inventor
C·L·帕克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of CN1437613A publication Critical patent/CN1437613A/zh
Application granted granted Critical
Publication of CN1298738C publication Critical patent/CN1298738C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
CNB018116426A 2000-06-23 2001-06-21 修饰的麻疹病毒v蛋白 Expired - Fee Related CN1298738C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21365500P 2000-06-23 2000-06-23
US60/213,655 2000-06-23

Publications (2)

Publication Number Publication Date
CN1437613A CN1437613A (zh) 2003-08-20
CN1298738C true CN1298738C (zh) 2007-02-07

Family

ID=22795965

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018116426A Expired - Fee Related CN1298738C (zh) 2000-06-23 2001-06-21 修饰的麻疹病毒v蛋白

Country Status (17)

Country Link
US (1) US6664066B2 (cg-RX-API-DMAC7.html)
EP (1) EP1292615B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004513616A (cg-RX-API-DMAC7.html)
KR (1) KR100885325B1 (cg-RX-API-DMAC7.html)
CN (1) CN1298738C (cg-RX-API-DMAC7.html)
AT (1) ATE343589T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001267014B2 (cg-RX-API-DMAC7.html)
BR (1) BR0111827A (cg-RX-API-DMAC7.html)
CA (1) CA2409432C (cg-RX-API-DMAC7.html)
CY (1) CY1105842T1 (cg-RX-API-DMAC7.html)
DE (1) DE60124098T2 (cg-RX-API-DMAC7.html)
DK (1) DK1292615T3 (cg-RX-API-DMAC7.html)
ES (1) ES2273852T3 (cg-RX-API-DMAC7.html)
IL (1) IL153004A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02012256A (cg-RX-API-DMAC7.html)
PT (1) PT1292615E (cg-RX-API-DMAC7.html)
WO (1) WO2002000694A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291925T1 (de) * 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
WO2004113517A2 (en) 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
DE102004042546A1 (de) * 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
US20090017517A1 (en) * 2007-07-13 2009-01-15 Medimmune, Llc Preparation of Negative-Stranded RNA Viruses by Electroporation
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
JP5721441B2 (ja) 2008-01-31 2015-05-20 キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ 免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2449113B8 (en) 2010-07-30 2015-11-25 CureVac AG Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
CN104471064B (zh) * 2012-01-20 2018-11-02 中华人民共和国香港特别行政区政府 副粘病毒及其用途
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US9552559B2 (en) 2014-05-06 2017-01-24 Elwha Llc System and methods for verifying that one or more directives that direct transport of a second end user does not conflict with one or more obligations to transport a first end user
US10458801B2 (en) 2014-05-06 2019-10-29 Uber Technologies, Inc. Systems and methods for travel planning that calls for at least one transportation vehicle unit
US11100434B2 (en) 2014-05-06 2021-08-24 Uber Technologies, Inc. Real-time carpooling coordinating system and methods
CN117010535A (zh) 2014-05-06 2023-11-07 优步技术公司 用于要求至少一个运输车辆单元的出行计划的系统和方法
WO2016009044A1 (en) * 2014-07-18 2016-01-21 Institut National De La Santé Et De La Recherche Médicale (Inserm) Peptides including a binding domain of the viral phosphoprotein (p) subunit to the viral rna free nucleoprotein (n0)
US9911170B2 (en) 2014-08-21 2018-03-06 Uber Technologies, Inc. Arranging a transport service for a user based on the estimated time of arrival of the user
US10685416B2 (en) 2015-12-10 2020-06-16 Uber Technologies, Inc. Suggested pickup location for ride services
US10731998B2 (en) 2017-11-05 2020-08-04 Uber Technologies, Inc. Network computer system to arrange pooled transport services

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013501A2 (en) * 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
WO1999049017A2 (en) * 1998-03-26 1999-09-30 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013501A2 (en) * 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
WO1999049017A2 (en) * 1998-03-26 1999-09-30 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b

Also Published As

Publication number Publication date
DE60124098D1 (de) 2006-12-07
DK1292615T3 (da) 2007-02-19
BR0111827A (pt) 2003-05-20
DE60124098T2 (de) 2007-04-05
CA2409432C (en) 2010-08-03
JP2004513616A (ja) 2004-05-13
ES2273852T3 (es) 2007-05-16
CY1105842T1 (el) 2011-02-02
US6664066B2 (en) 2003-12-16
ATE343589T1 (de) 2006-11-15
WO2002000694A3 (en) 2002-10-10
EP1292615A2 (en) 2003-03-19
CN1437613A (zh) 2003-08-20
PT1292615E (pt) 2007-01-31
AU6701401A (en) 2002-01-08
AU2001267014B2 (en) 2007-03-15
WO2002000694A2 (en) 2002-01-03
CA2409432A1 (en) 2002-01-03
KR20030032971A (ko) 2003-04-26
MXPA02012256A (es) 2003-04-25
EP1292615B1 (en) 2006-10-25
US20030206925A1 (en) 2003-11-06
KR100885325B1 (ko) 2009-02-25
IL153004A0 (en) 2003-06-24

Similar Documents

Publication Publication Date Title
CN1437613A (zh) 修饰的麻疹病毒v蛋白
CN1187088C (zh) 嵌合黄病毒疫苗
CN1871355A (zh) 从cDNA中回收非节段性负链RNA病毒的改进方法
AU2001267014A1 (en) Modified morbillivirus V proteins
CN1620500A (zh) 包含功能性缺失的基因组的冠状病毒样颗粒
CN1829799A (zh) 含polii启动子和核酶的重组流感载体
CN1788088A (zh) 突变的水泡性口炎病毒及其用途
CN1833022A (zh) 包含HCV的多蛋白NS3/NS4和多肽NS5b的组合物,包括相应核酸序列的表达载体及它们的治疗应用
CN1524088A (zh) 在易感哺乳动物中引起呼吸道疾病的病毒
CN1602316A (zh) 黄病毒ns1亚单位疫苗
CN1384877A (zh) 从cDNA拯救腮腺炎病毒
CN1402792A (zh) 减毒的人－牛嵌合呼吸道合胞病毒疫苗的生产
CN1556857A (zh) 呼吸道合胞病毒(rsv)g蛋白的新肽及其在疫苗中的应用
CN1347458A (zh) 从克隆的核苷酸序列制备减毒负链rna病毒疫苗
CN1688702A (zh) 表达rna病毒抗原表位的重组麻疹病毒在制备疫苗组合物中的用途
CN1492923A (zh) 减毒的活疫苗
CN1455816A (zh) 从cDNA中挽救犬热病病毒
CN1652819A (zh) 间质肺炎病毒的减毒
CN1196780C (zh) Rna病毒拯救的方法
CN1384883A (zh) 表达免疫调节分子的重组呼吸道合胞病毒的制备
CN1369011A (zh) 减毒的人－牛嵌合副流感病毒(piv)疫苗
CN1364195A (zh) 从克隆的核苷酸序列制备减毒嵌合呼吸道合胞毒病毒
CN1898390A (zh) 用于在改良安卡拉痘苗病毒中进行表达的启动子
CN1304452A (zh) 减毒瘟病毒
CN1198918C (zh) 减毒的活胸膜肺炎放线杆菌

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070207

Termination date: 20120621